Overview

Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well a repeat or single liposomal bupivacaine injection (quadratus lumborum block) works in reducing opioid prescriptions after surgery in patients with retroperitoneal sarcoma. Liposomal bupivacaine is a numbing medication. Giving a second injection block may decrease dependency on opioid medications for pain relief after surgery and prevent long-term use and addiction.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Analgesics, Opioid
Bupivacaine